Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + dolutegravir sodium + abacavir
- Development stage
- Approved
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lamivudine + dolutegravir sodium + abacavir is an oral fixed-dose combination antiretroviral therapy for **HIV-1 infection** developed by ViiV Healthcare. It combines **dolutegravir sodium**, an HIV integrase strand transfer inhibitor that blocks viral DNA integration into the host genome, with **abacavir** and **lamivudine**, two nucleoside analogue reverse transcriptase inhibitors that inhibit HIV reverse transcriptase and terminate viral DNA synthesis. Marketed as **Triumeq** and the pediatric dispersible formulation **Triumeq PD**, it is used as a once-daily combination regimen in adults and pediatric patients, but it is not recommended as a complete regimen when integrase inhibitor resistance is suspected because the fixed dolutegravir dose may be insufficient in that setting.
- Brand names
- TriumeqTriumeq PD
- Other names
- abacavir + dolutegravir sodium + lamivudinedolutegravir sodium + abacavir + lamivudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePOLB (DNA polymerase beta)Integrase allosteric pocket (HIV)POLG (Mitochondrial DNA polymerase gamma)POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on lamivudine + dolutegravir sodium + abacavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + dolutegravir sodium + abacavir.